Jove
Visualize
Contact Us

Related Experiment Videos

Emerging drugs in psoriasis.

Robert Gniadecki1, Martin J Calverley

  • 1Department of Dermatology, Bispebjerg Hospital, DK-2400 Copenhagen NV, Denmark. rgniadecki@hotmail.com

Expert Opinion on Emerging Drugs
|July 2, 2005
PubMed
Summary

Psoriasis, an autoimmune skin disorder, has seen advancements in understanding its immunopathogenesis. New biologic therapies targeting immune responses and cytokines show promise for treating this chronic condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The risk and prevalence of hepatic diseases in psoriasis: A systematic review and meta-analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Severe fatigue is associated with diminished lung function and elevated Galectin-9 levels in early systemic sclerosis.

Frontiers in immunology·2025
Same author

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.

The British journal of dermatology·2025
Same author

Time-Driven Strategies for Inflammatory Skin Diseases: A Circadian Approach.

Journal of cutaneous medicine and surgery·2025
Same author

Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report.

SAGE open medical case reports·2025
Same author

Merkel cell carcinoma in a psoriasis patient on long-term ixekizumab therapy: A case report.

SAGE open medical case reports·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a common chronic inflammatory autoimmune skin disease.
  • It involves accelerated epidermal proliferation and disordered differentiation.
  • Affects 1-2% of the population in developed countries.

Purpose of the Study:

  • To review progress in understanding psoriasis immunopathogenesis.
  • To highlight new therapeutic approaches and drugs.
  • To identify potential future treatment targets.

Main Methods:

  • Review of recent clinical trials and scientific literature.
  • Analysis of novel biotechnology approaches.
  • Identification of emerging therapeutic targets.

Main Results:

  • Significant progress in understanding disease immunopathogenesis since 1999.
  • Efficacy demonstrated for biologics targeting tumor necrosis factor-alpha and T-cell pathways (e.g., anti-CD2, anti-CD11a, anti-B7, anti-CD4, anti-CD25).
  • Promising results for agents blocking type 1 cytokines or skewing immune responses to type 2.

Conclusions:

  • Novel biologic therapies targeting specific immune pathways offer effective psoriasis treatment.
  • Future strategies may involve targeting chemokines, T-cell trafficking, or peroxisome proliferator-activated receptors.
  • Limited development reported for drugs targeting keratinocytes or traditional antipsoriatic agents.

Related Experiment Videos